Vebreltinib Clinical Trials

4 actively recruiting trials

▲ +1 trial since June 2026

Also known as: BoRuiTiNi, Bozitinib, PLB1001

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

Avistone Biotechnology Co., Ltd.2
Second Affiliated Hospital, School of Medicine, Zhejiang University1
Second Affiliated Hospital of Nanchang University1

Indications

Cancer4
Lung Cancer3
Non Small Cell Lung Cancer3
Clear Cell Sarcoma (CCS)1

Other4 trials

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Phase 1/2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Phase 2

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Phase 1/2

Vebreltinib for Advanced or Metastatic CCS

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.